Extremity Leiomyosarcoma Metastasizing to the Large Bowel As a Pedunculated Colon Polyp

Ipach, Ingmar; Weyhern, Claus Hann von; Kopp, Hans‐Georg; Kunze, Beate; Kluba, Torsten

doi:10.1200/jco.2011.37.0221

Cited by 6 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Actually, LMS of the left thigh that metastasized to the liver, large bowel and lymph nodes has been reported [12]. However, in the present study, soft tissue tumor was not detected using periodically-performed CT and PET-CT scans in the course of treatment.…”

Section: Discussioncontrasting

confidence: 60%

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

et al. 2012

View full text Add to dashboard Cite

BackgroundLeiomyosarcoma (LMS) of the gastrointestinal tract is an extremely rare high-grade neoplasm with poor prognosis. For advanced LMS with distant metastasis, the decision as to the choice of the most appropriate therapeutic strategy, including chemotherapy and surgery, is difficult. Here, we present an unusual case of LMS of the sigmoid colon with liver metastases and gastric cancer. The survival of this patient was prolonged by a combined modality therapy involving chemotherapy and surgery.Case presentationA 66-year-old woman who had been diagnosed with advanced gastric cancer and multiple liver metastases was referred to our hospital. The initial treatment with docetaxel and S-1 considerably reduced both the gastric cancer and liver tumors; consequently we performed surgical resection. Pathological examination revealed that no viable tumor cells remained in the stomach and chemotherapy resulted in complete remission of the gastric cancer. The liver tumors were immunohistochemically diagnosed as LMS. A tumor of the sigmoid colon was subsequently discovered and the liver tumors were found to have recurred. The surgically resected sigmoid colon and liver tumors were all immunohistochemically diagnosed as LMS. These findings indicated that the multiple liver metastases arose from the LMS in the sigmoid colon, and that they were accompanied by advanced gastric cancer. We performed another surgical resection and administered chemotherapy to treat the recurring liver metastases. The patient survived for 4 years and 10 months after initial presentation at our hospital.ConclusionColonic LMS is rare and its joint occurrence with gastric cancer is extremely unusual. Although LMS is a high-grade neoplasm, a multimodal therapeutic approach can increase patient survival time even when multiple liver metastases are present.

show abstract

Section: Discussioncontrasting

confidence: 60%

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Soft tissue LMS is rarely seen in the extremities, comprising about 10% - 15% of extremity sarcomas 2. Extremity soft tissue LMS can metastasize to distant sites such as lungs, bones, and other organs at an early stage 11. Despite intensive treatment, patients with extremity STS and metastasis usually had a poor prognosis 12-14.…”

Section: Discussionmentioning

confidence: 99%

Surgery plus chemotherapy improves survival of patients with extremity soft tissue leiomyosarcoma and metastasis at presentation

Qian

Zhan

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Purpose : Extremity soft tissue leiomyosarcoma (LMS) with metastasis is a rare disease with a poor prognosis. The purpose of our study was to define clinical features of extremity soft tissue LMS with metastasis as well as to identify multivariable predictors of survival. Methods : During 1973-2015, 239 patients with metastatic extremity soft tissue LMS were identified from the Surveillance, Epidemiology, and End Results (SEER) program database. The prognostic analysis was performed using the Kaplan-Meier method and a Cox proportional hazards regression model. Results : This group comprised 126 females (52.7%) and 113 males (47.3%), whose ages ranged from 8 to 95 years (median 67 years). The overall survival (OS) and cancer-specific survival (CSS) rates of the entire group at 3 years were 22.6% and 23.4%, respectively. The median OS and CSS were 14.0±1.5 and 15.0±2.3 months, respectively. Multivariate analysis revealed that tumor size >10 cm, no surgery and no chemotherapy were independent risk factors of decreased OS and CSS. Radiotherapy was not significantly associated with OS or CSS. Conclusion : Extremity soft tissue LMS patients who present with metastasis at diagnosis had a poor prognosis. Patients who performed surgery for primary tumors and chemotherapy had a better chance for prolonged survival.

show abstract

“…LMS is relatively rare representing 10–20% of soft tissue sarcomas . It can appear at almost all anatomic sites such as the uterus , retroperitoneum , extremities , and blood vessels . Uterine LMS is the most common site‐specific group with an estimated incidence of 0.64 cases per 100,000 women .…”

Section: Introductionmentioning

confidence: 99%

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

et al. 2016

View full text Add to dashboard Cite

Advanced stage leiomyosarcoma (LMS) is incurable with current systemic antitumor therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat LMS. We reviewed the medical records of 75 consecutive patients with histologically confirmed metastatic LMS, who had been referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. To lay the foundation for potential phase I trials for the treatment of advanced LMS, we analyzed tumor response and survival outcome data. The frequent hotspot gene aberrations that we observed were the TP53 mutation (65%) and RB1 loss/mutation (45%) detected by Sequenom or next‐generation sequencing. Among patients treated with gene aberration‐related phase I trial therapy, the median progression‐free survival was 5.8 months and the median overall survival was 15.9 months, significantly better than in patients without therapy (1.9 months, P = 0.001; and 8.7 months, P = 0.013, respectively). Independent risk factors that predicted shorter overall survival included hemoglobin <10 g/dL, body mass index <30 kg/m2, serum albumin <3.5 g/dL, and neutrophil above upper limit of normal. The median survivals were 19.9, 7.6, and 0.9 months for patients with 0, 1 or 2, and ≥3 of the above risk factors, respectively (P < 0.001). A prognostic scoring system that included four independent risk factors might predict survival in patients with metastatic LMS who were treated in a phase I trial. Gene aberration‐related therapies led to significantly better clinical benefits, supporting that further exploration with novel mechanism‐driven therapeutic regimens is warranted.

show abstract

Extremity Leiomyosarcoma Metastasizing to the Large Bowel As a Pedunculated Colon Polyp

Cited by 6 publications

References 25 publications

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report

Surgery plus chemotherapy improves survival of patients with extremity soft tissue leiomyosarcoma and metastasis at presentation

Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience

Contact Info

Product

Resources

About